A1Melanoma HMB-45 (Malignant Melanoma, Brain metastasis, stage IV) | B1EGFR (Breast Carcinoma) | C1EPCAM (Metastatic Breast Cancer from pleural effusion) | D1HER-2 neu (Metastatic Breast Cancer from pericardial effusion) | E1Ki-67 (Human HSIL Cervical Cancer) | F1Ki-67 (Metastatic Prostate Cancer from Lymph Node) | G1CD8 (Acute Lymphoblastic Keukemia) | H1B7-H3 (Mesothelioma) |
A2Melanoma HMB-45 (Malignant Melanoma, Lymph node metastasis, stage III) | B2Ki-67 (Breast Ductal Carcinoma) | C2ER (Metastatic Breast Cancer from pleural effusion) | D2CK-cocktail (Metastatic Ductal Breast Cancer from pleural effusion) | E2Ki-67 (Human Cervical Cancer Adenocarcinoma) | F2CK-Cocktail (Colorectal Adenocarcinoma) | G2LAG-3 (Myelomonocytic Leukemia) | H2ALK-1 (Non-Small Cell Lung Cancer) |
A3Melanoma HMB-45 (Metastatic Melanoma, derived from metastasis to skin) | B3Her-2 (Metastatic Breast Cancer from Pleural Effusion) | C3CK-Cocktail (Metastatic Breast Cancer from pleural effusion) | D3Myogenin (Rhabdomyosarcoma) | E3Ki-67 (Human Epidermoid Cervical Cancer Metastasis) | F3LAG-3 (Embryonic Kidney) | G3CD117 (Acute Myologenous Leukemia) | H3EPCAM (Lung Cancer) |
A4Melanoma HMB-45 (Malignant Melanoma, Skin) | B4PR (Ductal Breast Cancer) | C4PR (Metastatic Breast Cancer from pleural effusion) | D4Neuroblastoma (Neuroblastoma Derived from Bone Marrow Metastasis) | E4Neuroblastoma (Neuroblastoma) | F4CTLA-4 (Normal Fibroblast) | G4BLANK | H4Ki-67 (Lung Papillary Adenocarcinoma) |
| Intended Use | For Laboratory Use | |||||||||
| Summary and Explanation | The 31-Core Human Cancer Cell Line Microarray consist of 31 – 2 mm cores of formalin-fixed paraffin-embedded cell lines which were assembled in array fashion to allow multiplex molecular pathology analysis and validation of reagents, or to be used as tissue controls for Immunohistochemistry and/or in situ hybridization (CISH and FISH) applications. | |||||||||
| Presentation | Five 31 – 2 mm cores, mounted on Hydrophilic Plus Slides (BSB 7028) are provided in a plastic mailer. | |||||||||
| Availability |
| |||||||||
